Business
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will take place November 5 to 9, 2025, in
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/f6083a0d9b38ae9032962f2dbc7ada9e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/58.9AQroXMUcFrnUKvXjLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f6083a0d9b38ae9032962f2dbc7ada9e","width":300,"height":56}},"lazy":false},{"type":"text","content":"Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will take place November 5 to 9, 2025, in National Harbor, Maryland, USA.","length":537,"tagName":"p"},{"type":"text","content":"Poster details","length":14,"tagName":"p"},{"type":"text","content":"Title: “Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized Phase 1 trial for locally advanced resected HPV negative HNSCC”.","length":202,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster and abstract number: 502","length":31,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: November 8, 2025","length":22,"tagName":"p"}]},{"val":[{"type":"text","content":"Author: C. Le Tourneau","length":22,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":75,"olType":false},{"type":"text","content":"The abstract will be available on the SITC website on November 4, 2025, at 9 a.m. ET.","length":85,"tagName":"p"},{"type":"text","content":"TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166).","length":372,"tagName":"p"},{"type":"text","content":"Transg...